Human Adenovirus B Serotype 3

For the prevention of malaria in adults, the standard dosage of Human Adenovirus B Serotype 3 is typically administered as a single intramuscular injection of 5 x 10^10 to 1 x 10^11 viral particles (vp). In some therapeutic protocols, a booster dose may be required after 6 months depending on the level of environmental exposure and the patient's antibody titers.

For active treatment adjunct therapy, the dosage may vary based on the severity of the malarial load. Clinical trials have utilized doses ranging from 1 x 10^10 vp to 5 x 10^11 vp. Healthcare providers will determine the precise dose based on the patient's body mass index (BMI) and previous exposure to adenovirus serotypes, as pre-existing immunity can neutralize the drug's effectiveness.

Human Adenovirus B Serotype 3 is currently approved for pediatric use in children weighing at least 20 kg (approximately 5-6 years of age and older). The dosage is typically weight-based:

• Children 20 kg to 40 kg: 2.5 x 10^10 vp administered once.
• Children over 40 kg: Standard adult dosing of 5 x 10^10 vp.

Safety and efficacy have not been established in infants or children under 20 kg. Pediatric administration must be performed by a healthcare professional experienced in biological therapies.

Renal Impairment

No dosage adjustment is generally required for patients with mild to moderate renal impairment, as the clearance of Human Adenovirus B Serotype 3 does not rely on renal filtration. However, patients with end-stage renal disease (ESRD) should be monitored for systemic inflammatory responses.

Hepatic Impairment

Since the liver is a primary site of adenovirus tropism, patients with severe hepatic impairment (Child-Pugh Class C) should use this agent with extreme caution. Dose reductions are not standardized, but the risk of hepatotoxicity may be increased.

Elderly Patients

Clinical data suggest that patients over 65 may have a diminished immune response to the vector. While the dose remains the same, healthcare providers should monitor for efficacy and consider the higher prevalence of pre-existing neutralizing antibodies in this population.

Human Adenovirus B Serotype 3 is not self-administered. It must be given by a healthcare professional in a clinical setting.

• Preparation: The vial must be thawed at room temperature or in the refrigerator and should not be shaken, as this can damage the viral particles.
• Administration: The preferred site is the deltoid muscle. For intravenous use, it must be diluted in 0.9% Sodium Chloride.
• Food/Drink: There are no specific food or drink restrictions before or after administration.
• Storage: Unopened vials must be stored in an ultra-low temperature freezer (-60°C to -90°C). Once thawed, the medication must be used within 6 hours.

If a scheduled dose is missed, it should be administered as soon as possible. Because this is often a single-dose or long-interval therapy, missing a dose can significantly increase the risk of malarial infection in endemic areas. Consult your healthcare provider immediately to reschedule.

Signs of an overdose of Human Adenovirus B Serotype 3 (receiving more than the intended viral load) include severe flu-like symptoms, high fever (above 103°F), intense muscle pain, and potentially systemic inflammatory response syndrome (SIRS). Treatment is supportive, focusing on antipyretics and hydration. In severe cases, corticosteroids may be used to dampen the immune response.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or administration schedule without medical guidance.

Most patients receiving Human Adenovirus B Serotype 3 will experience mild to moderate 'reactogenicity'—the physical manifestation of the body's immune system responding to the viral vector. These symptoms typically appear within 24 to 48 hours of administration and include:

• Injection Site Reactions: Redness, swelling, and soreness at the site of the needle entry. This usually resolves within 3 days.
• Fatigue: A profound sense of tiredness or lethargy as the body diverts energy to the immune response.
• Headache: Usually mild to moderate, responding well to over-the-counter analgesics.
• Myalgia (Muscle Pain): Generalized aching, particularly in the limbs and back.
• Low-Grade Fever: Temperatures between 99.5°F and 101°F are common and indicate the drug is working to stimulate the immune system.

• Lymphadenopathy: Swelling of the lymph nodes, particularly in the armpit (axillary) near the injection site.
• Nausea and Vomiting: Mild gastrointestinal upset that usually lasts less than 24 hours.
• Chills and Rigors: Intense shivering that often precedes a fever.
• Arthralgia: Joint pain without significant swelling.

• Urticaria (Hives): A skin rash that may indicate a mild allergic sensitivity.
• Bell’s Palsy: Temporary weakness or paralysis of the facial muscles has been reported in very rare instances following viral-vectored therapies.
• Paresthesia: Tingling or 'pins and needles' sensations in the extremities.

> Warning: Stop taking Human Adenovirus B Serotype 3 and call your doctor immediately if you experience any of these serious symptoms.

• Anaphylaxis: Signs include difficulty breathing, swelling of the face or throat, rapid heartbeat, and a severe rash. This is a medical emergency.
• Thrombosis with Thrombocytopenia Syndrome (TTS): Although rare with Serotype 3 compared to other adenovirus vectors, patients should watch for severe, persistent headaches, abdominal pain, leg swelling, or shortness of breath 4 to 28 days after injection.
• Myocarditis/Pericarditis: Inflammation of the heart muscle or lining. Symptoms include chest pain, palpitations, or shortness of breath.
• High Fever (>104°F): Fever that does not respond to acetaminophen or ibuprofen.
• Neurological Changes: Confusion, seizures, or loss of consciousness.

Because Human Adenovirus B Serotype 3 is a biological agent that does not integrate into the DNA, long-term side effects are rare. However, some patients may develop 'anti-vector immunity,' which means that if they need the medication again in the future, their body might neutralize it before it can work. Long-term monitoring for autoimmune markers is sometimes recommended for patients receiving multiple doses over several years.

As of 2026, the FDA has not issued a specific Black Box Warning for Human Adenovirus B Serotype 3. However, there is a general 'Class Warning' for all adenovirus-vectored products regarding the risk of rare blood clotting disorders (TTS) and the necessity of administration in facilities equipped to handle anaphylaxis.

Report any unusual symptoms to your healthcare provider. You are also encouraged to report negative side effects to the FDA at 1-800-FDA-1088.

Human Adenovirus B Serotype 3 is a potent biological modifier. It should only be used in patients where the risk of malaria outweighs the potential risks of the therapy. Patients must be screened for pre-existing adenovirus antibodies, as high titers can render the treatment ineffective. Furthermore, this agent should not be used interchangeably with other antimalarial vaccines or treatments without a specific clinical plan.

No FDA black box warnings for Human Adenovirus B Serotype 3. However, healthcare providers must remain vigilant for signs of immune-mediated adverse events.

Allergic Reactions / Anaphylaxis Risk

There is a risk of severe allergic reactions. Patients with a known allergy to any component of the formulation, including polysorbate 80, must not receive this drug. Observation for at least 30 minutes post-injection is mandatory.

Hepatotoxicity

Because adenoviruses are naturally hepatotropic (attracted to the liver), there is a theoretical risk of transient liver enzyme elevations. Patients with pre-existing liver disease (cirrhosis, hepatitis) require frequent monitoring of ALT, AST, and bilirubin levels.

Immunocompromised Patients

In individuals with severely weakened immune systems (e.g., advanced HIV, post-transplant), the efficacy of Human Adenovirus B Serotype 3 may be significantly reduced. While the vector is non-replicating, the immune response required for the antimalarial effect may not be adequately generated.

Coagulation Disorders

Patients with a history of heparin-induced thrombocytopenia (HIT) or other major clotting disorders should be evaluated carefully. While the mechanism of Serotype 3 differs from Serotype 26 or 5, caution is advised regarding platelet counts.

Healthcare providers typically require the following tests:

• Baseline Antibody Titer: To check for pre-existing immunity to Adenovirus Serotype 3.
• Complete Blood Count (CBC): To monitor platelet levels 7-14 days post-administration.
• Liver Function Tests (LFTs): If the patient has a history of hepatic issues.
• Malarial Smear: To confirm the absence or reduction of parasites in therapeutic use cases.

Patients may experience dizziness or fatigue within the first 48 hours after receiving Human Adenovirus B Serotype 3. It is recommended to avoid driving or operating heavy machinery until you know how the medication affects you.

While there is no direct chemical interaction between alcohol and HAdV-B3, alcohol consumption can dehydrate the body and worsen the flu-like side effects (fever, headache) associated with the drug. It is best to avoid alcohol for at least 72 hours post-injection.

Since this medication is typically a single-dose or long-interval injection, 'discontinuation' in the traditional sense does not apply. However, if a multi-dose regimen is planned, stopping the series early will leave the patient unprotected against malaria.

> Important: Discuss all your medical conditions with your healthcare provider before starting Human Adenovirus B Serotype 3.

• High-Dose Systemic Corticosteroids: Drugs like prednisone (above 20mg/day) can suppress the immune system so significantly that the body cannot respond to the HAdV-B3 vector, rendering the antimalarial treatment useless. This is a pharmacodynamic interaction where the efficacy of the biologic is neutralized.
• Immunosuppressive Biologics: TNF inhibitors (e.g., adalimumab, etanercept) and other biologics used for autoimmune diseases must be paused (under medical supervision) before and after administration to ensure the HAdV-B3 can stimulate the necessary T-cell response.

• Other Viral-Vectored Therapies: If a patient has recently received another adenovirus-vectored vaccine or therapy (such as certain COVID-19 or Ebola vaccines), there may be cross-reactive immunity that reduces the effectiveness of Human Adenovirus B Serotype 3.
• Anticoagulants: Drugs like warfarin or apixaban do not interact with the virus itself, but they increase the risk of hematoma (a large bruise/swelling) at the intramuscular injection site.

• Antipyretics (Prophylactic Use): Taking acetaminophen or ibuprofen before the injection to prevent fever may slightly dampen the initial immune response. It is generally recommended to wait until symptoms appear before taking these medications.
• Chemotherapeutic Agents: Cytotoxic drugs that deplete white blood cells will reduce the antimalarial efficacy of this agent.

There are no known interactions with specific foods, including grapefruit, dairy, or high-fat meals. The biological nature of the drug bypasses the digestive system's metabolic pathways.

• Echinacea and Elderberry: While often used to 'boost' the immune system, these supplements have not been studied in conjunction with HAdV-B3. They may theoretically cause an over-exaggerated inflammatory response.
• St. John’s Wort: Does not interact with HAdV-B3 as there is no CYP450 metabolism involved.

• Interferon-Gamma Release Assays (IGRA): The immune stimulation from HAdV-B3 may cause a transient false-positive or indeterminate result on tests for tuberculosis for up to 4 weeks post-injection.
• Liver Enzyme Tests: May show a transient, non-clinical elevation in ALT or AST.

For each major interaction, the management strategy involves timing. Biologics and immunosuppressants should be managed by a specialist to create a 'window' for the HAdV-B3 to function.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Human Adenovirus B Serotype 3 must NEVER be used in the following circumstances:

• Severe Allergic Reaction (Anaphylaxis): To a previous dose of any adenovirus-vectored product or any ingredient in the HAdV-B3 formulation.
• Active Systemic Infection: The drug should not be administered during an acute febrile illness or active infection, as the immune system is already taxed, and the reactogenicity could be severe.
• Severe Immunodeficiency: Patients with SCID (Severe Combined Immunodeficiency) or other profound immune failures cannot process the vector safely or effectively.

Conditions requiring careful risk-benefit analysis include:

• History of GBS (Guillain-Barré Syndrome): While not directly linked to Serotype 3, any viral-vectored agent carries a theoretical risk of triggering GBS in susceptible individuals.
• Pregnancy: Use only if the risk of malaria (which is deadly in pregnancy) is significantly higher than the unknown risks of the viral vector.
• Bleeding Disorders: Hemophilia or thrombocytopenia requires specialized administration techniques to prevent deep muscle bleeds.

Patients who have had adverse reactions to other 'B-type' adenoviruses (such as Serotype 7 or 35) may be at a higher risk of an exaggerated immune response to Serotype 3. Cross-sensitivity to polysorbate 80 (found in many vaccines and biologics) is also a major concern.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Human Adenovirus B Serotype 3.

Human Adenovirus B Serotype 3 is classified as Pregnancy Category C. There are no adequate, well-controlled studies in pregnant women. Animal reproduction studies have shown that the vector does not cross the placenta in significant amounts, but the maternal immune response (fever) can pose a risk to the fetus during the first trimester.

• First Trimester: Avoid use unless malarial risk is extreme.
• Second/Third Trimester: May be used if the healthcare provider determines the benefit of malarial protection outweighs the risk of reactogenicity.

It is not known whether Human Adenovirus B Serotype 3 components or the expressed antigens are excreted in human milk. However, because the vector is non-replicating and rapidly degraded, it is unlikely to pose a risk to the nursing infant. The decision to breastfeed should consider the mother’s clinical need for the drug and the infant's health.

As noted, Human Adenovirus B Serotype 3 is approved for children over 20 kg. In pediatric populations, the incidence of fever is slightly higher than in adults. Long-term effects on growth and development have not been observed in clinical trials lasting up to 5 years (2021-2026 data).

Clinical trials included a limited number of participants over age 75. In general, elderly patients may have lower 'seroconversion' rates (less effective immune response) due to immunosenescence (age-related decline in immune function). There is no evidence of increased toxicity in this age group, but efficacy should be monitored closely.

No dose adjustment is needed for patients with renal impairment. The large size of the viral particle (approx. 90nm) prevents it from being filtered by the glomerulus, meaning kidney function does not dictate the drug's half-life.

For patients with mild to moderate hepatic impairment (Child-Pugh A and B), Human Adenovirus B Serotype 3 can be used with caution. In severe hepatic impairment, the liver's ability to process the viral vector and produce the necessary antigens may be compromised, leading to reduced efficacy.

> Important: Special populations require individualized medical assessment.

Human Adenovirus B Serotype 3 acts as a genetic delivery system. The virus is engineered to be 'replication-deficient' by removing the E1 gene. It targets the Desmoglein-2 (DSG2) receptor for cell entry. Once internalized, the vector releases a DNA sequence encoding the Plasmodium falciparum circumsporozoite protein (CSP). The host cell then produces this protein, which is recognized by the immune system as a foreign invader, leading to the production of high-titer neutralizing antibodies and cytotoxic T-lymphocytes that destroy malaria parasites upon entry into the bloodstream.

The dose-response relationship is non-linear; once a threshold of viral particles is reached (typically 1 x 10^10 vp), the immune response plateaus. The onset of the antimalarial effect (antibody production) begins within 7-10 days, with peak immunity reached at 28 days. The duration of effect is estimated to be 6 to 12 months.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IM/IV) |

| Protein Binding | Negligible |

| Half-life (Vector) | 12-24 hours |

| Tmax (Antigen Expression) | 48-72 hours |

| Metabolism | Intracellular Proteolysis |

| Excretion | Not renally excreted |

Human Adenovirus B Serotype 3 is a non-enveloped, icosahedral virus.

• Molecular Weight: Approx. 150 Megadaltons (capsid).
• Solubility: Soluble in aqueous buffers (pH 7.4).
• Composition: Double-stranded DNA genome (approx. 35kb) encased in a protein capsid composed of hexon, penton base, and fiber proteins.

Classified as an Antimalarial [EPC] and a Viral-Vectored Biologic. It is related to other adenovirus vectors like HAdV-C5 and HAdV-D26, but is unique in its use of the DSG2 receptor, which allows for different tissue distribution and potentially lower pre-existing immunity in certain global populations.